治疗相关骨髓增生异常综合征应获得特定的诊断亚分类和风险分层——一种对t-MDS患者进行分类的方法
分析2087例来自不同国际MDS组的t-MDS患者,评估分类与预后工具,并与4593例原发性MDS(p-MDS)比较。应用p-MDS的WHO分类可有效预测t-MDS的转化时间和生存(均p < 0.001)。各t-MDS亚组结局均劣于p-MDS亚组,但FAB和WHO分类、IPSS-R和WPSS-R均能有效区分t-MDS风险组,细胞遗传学特征预测力增强。
要点
- 应用p-MDS的WHO分类可有效预测t-MDS的转化时间和生存(均p < 0.001)。
- t-MDS与p-MDS同样异质,各t-MDS亚组结局均劣于对应p-MDS亚组。
- FAB和WHO分类、IPSS-R和WPSS-R均能有效区分t-MDS风险组,细胞遗传学预测力增强。
核心结论
- 数据强烈支持将t-MDS归类为独立于其他WHO分类的治疗相关髓系肿瘤的独立实体,以增强治疗决策并促进t-MDS患者纳入临床研究。
研究设计与样本
- 分析2087例来自不同国际MDS组的t-MDS患者数据,以评估分类和预后工具,并与国际MDS预后工作组数据库(IWG-PM)中4593例原发性MDS(p-MDS)患者进行比较。
主要发现
- 应用p-MDS的WHO分类可有效预测t-MDS的转化时间和生存(均p < 0.001)。
- 各t-MDS亚组结局均劣于对应p-MDS亚组,但FAB和WHO分类、IPSS-R和WPSS-R均能有效将t-MDS患者分为不同风险组。
- 所有已建立的p-MDS风险因素在t-MDS中保持相关性,其中细胞遗传学特征预测力增强。
关键数值与推荐
- 应用p-MDS的WHO分类预测t-MDS转化时间和生存的p值均< 0.001。
- FAB和WHO分类、IPSS-R和WPSS-R均能有效区分t-MDS风险组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related acute myeloid leukemia (AML) and t-myelodysplastic/myeloproliferative neoplasms into one subgroup independent of morphologic or prognostic features. Analyzing data of 2087 t-MDS patients from different international MDS groups to evaluate classification and prognostication tools we found that applying the WHO classification for p-MDS successfully predicts time to transformation and survival (both p < 0.001). The results regarding carefully reviewed cytogenetic data, classifications, and prognostic scores confirmed that t-MDS are similarly heterogeneous as p-MDS and therefore deserve the same careful differentiation regarding risk. As reference, these results were compared with 4593 primary MDS (p-MDS) patients represented in the International Working Group for Prognosis in MDS database (IWG-PM). Although a less favorable clinical outcome occurred in each t-MDS subset compared with p-MDS subgroups, FAB and WHO-classification, IPSS-R, and WPSS-R separated t-MDS patients into differing risk groups effectively, indicating that all established risk factors for p-MDS maintained relevance in t-MDS, with cytogenetic features having enhanced predictive power. These data strongly argue to classify t-MDS as a separate entity distinct from other WHO-classified t-myeloid neoplasms, which would enhance treatment decisions and facilitate the inclusion of t-MDS patients into clinical studies.
引用
- Kuendgen A, Nomdedeu M, Tuechler H, et al. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Leukemia. 2020. PMID: 32595214. doi:10.1038/s41375-020-0917-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。